Volume : 1, Issue : 1, NOV 2015

PHARMACOLOGICAL, PHARMACEUTICAL AND SAFETY PROFILE OF SUVOREXANT: A DUAL OREXIN RECEPTORS ANTAGONIST FOR TREATMENT OF INSOMNIA

Sadaf Ali, Zubair Ahmed, Aftab Ahmad, Shah Alam Khan, Asif Husain

Abstract

Insomnia is the most common sleeping disorder affecting population with or without other medical or psychiatric disorders. It affects more than 30% of the adult population and causes wide range of health problems like hypertension, obesity, diabetes, heart attack and stroke. Despite the availability of a number of drugs, insomnia is still a serious medical issue. The orexin (OX and OX ) receptors are G-protein-coupled receptors 1 2 which have key roles in the regulation of sleep-wake cycles. Suvorexant (also known as MK-4305) is a selective, dual orexin receptors antagonist, R used in the treatment of insomnia. Suvorexant is available in the market under the brand name of Belsomra . Suvorexant is considered as an effective treatment for insomnia, and reported to be well-tolerated by patients. This review presents updated information on the pharmaceutical and pharmacological description of Suvorexant.

Keywords

Belsomra, Sleep disorder, receptor, hypocretin

Article : Download PDF

Cite This Article

Article No : 9

Number of Downloads : 415

References

[1] Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy,
safety and place in therapy. Ther Adv Drug Saf. 2015;6(5):189-
195.
[2] Buysse DJ.Chronic insomnia. Am J Psychiatry 2008;165(6):
678-686.
[3] Milton K. Erman MD. Insomnia: Comorbidities and Consequences".
Primary Psychiatry 2007;14(6): 31-35.
[4] Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and
consequences. Clin Cornerstone. 2003;5(3):5-15.
[5] Http://sleepdisorders.about.com/od/commonsleepdisorders
/a/Acute_Insomnia.htm.Acute Insomnia – What is Acute Insomnia.
Retrieved on 3rd November 2015.
[6] Schenkein J, Montagna P. Self management of fatal familial
insomnia. Part 1: what is FFI? MedGenMed. 2006;8(3):65.
[7] The Family That Couldn't Sleep: A Medical Mystery.
http://www.amazon.com/The- Family-That-Couldnt-
Sleep/dp/081297252X. Retrieved on 3rd November 2015.
[8] Tal JZ, Suh SA, Dowdle CL, Nowakowski S. Treatment of
Insomnia, Insomnia Symptoms, and Obstructive Sleep Apnea
During and After Menopause: Therapeutic Approaches. Curr
Psychiatry Rev.2015;11(1):63-83.
[9] Ebert B, Wafford KA, Deacon S. Treating insomnia: Current and
investigational pharmacological approaches. Pharmacol Ther.
2006; 112(3):612-29.
[10]Sarrecchia C, Sordillo P, Conte G, Rocchi G. Barbiturate withdrawal
syndrome: a case associated with the abuse of a headache
medication.[Article in Italian]. Ann Ital Med Int.
1998;13(4):237-239.
[11] Proud foot H, Teesson M. Australian National Survey of Mental
Health and Wellbeing. Who seeks treatment for alcohol dependence?
Findings from the Australian National Survey of Mental
Health and Wellbeing. Soc Psychiatry Psychiatr Epidemiol.
2002;37(10):451-6.
[12] Https://en.wikipedia.org/wiki/Hypnotic/ Retrieved on 3rd
November 2015.
[13] Yi PL, Tsai CH, Chen YC, Chang FC. Gamma-amino butyric
acid (GABA) receptor mediates suanzaorentang, a traditional
Chinese herb remedy, -induced sleep alteration. J Biomed Sci.
2007; 14(2):285-297.
[14] Davis JF, Choi DL, Benoit SC. Chapter 24. Orexigenic Hypothalamic
Peptides Behavior and Feeding - 24.5 Orexin". In Preedy
VR, Watson RR, Martin CR. Handbook of Behavior, Food and
Nutrition. Springer. 2011, pp. 361–2. ISBN 9780387922713
[15] Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S,
Kangawa K, Sakurai T, Yanagisawa M, and Nakazato M.
Orexins, orexigenic hypothalamic peptides, interact with autonomic,
neuroendocrine and neuroregulatory systems. Proc Natl
Acad Sci U S A. 1999; 96(2):748-753.
[16] Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM,
Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson
S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS,
McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma
DJ, Yanagisawa M. Orexins and orexin receptors: a family of
hypothalamic neuropeptides and G protein-coupled receptors
that regulate feeding behavior. Cell.1998;92(4):573-585.
[17] Http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/
ucm409950.htm, Retrieved on 3rd November 2015.
[18] Patel KV, Aspesi AV, Evoy KE. Suvorexant: a dual orexin receptor
antagonist for the treatment of sleep onset and sleep maintenance
insomnia. Ann Pharmacother. 2015 ;49(4):477-483.
[19] Product Information: BELSOMRA(R) oral tablets, suvorexant
oral tablets. Merck Sharp & Dohme Corp. (per manufacturer),
Whitehouse Station, NJ, 2014.
[20] HCRTR1 hypocretin (orexin) receptor 1 [ Homo sapiens (human)
], Gene ID: 3061, updated on 4-Oct-2015, http://www.ncbi.nlm.
nih.gov/gene/3061;
[21] HCRTR2 hypocretin (orexin) receptor 2 [ Homo sapiens (human)
], Gene ID: 3062, updated on 28-Sep-2015, http://www.ncbi.nlm.
nih.gov/gene/3062;
[22] Cada DJ, Levien TL, Baker DE. Suvorexant. Hosp Pharm.
2015;50(1):59-71.
[23] Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment
of insomnia. Expert Rev Clin Pharmacol. 2014;7(6):711-
30.

[24] Http://www.drugs.com/belsomra.html, Retrieved on 3rd
November 2015.
[25] Dubey AK, Handu SS, Mediratta PK. Suvorexant: The first
orexin receptor antagonist to treat insomnia. J Pharmacol
Pharmacother. 2015;6(2):118-121.
[26] Reddy A, Puvvada SC, Kommisetti S, El-Mallakh RS, Lippmann
S. Suvorexant: something new for sleep? Acta
Neuropsychiatr. 2015; 27(1):53-55
[27] Traynor K. Suvorexant approved for insomnia. Am J Health
Syst Pharm. 2014 15; 71(18):1524.
[28] Yang LP. Suvorexant: first global approval. Drugs 2014;
74(15):1817-1822.
[29] Sheridan C. Insomniacs get new mechanism sleep drug
Belsomra. Nat Biotechnol.2014; 32(10):968.
[30] Riemann D, Spiegelhalder K. Orexin receptor antagonists: a
new treatment for insomnia? Lancet Neurol. 2014; 13(5):441-3.
[31] Howland RH. Suvorexant: a novel therapy for the treatment of
insomnia. J Psychosoc Nurs Ment Health Serv. 2014 ;52(10):23-
6.
[32] Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB,
Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M,
Lines C, Roth T, Herring WJ. Safety and efficacy of suvorexant
during 1-year treatment of insomnia with subsequent abrupt
treatment discontinuation: a phase 3 randomised, double-blind,
placebo-controlled trial. Lancet Neurol. 2014;13(5):461-471.
[33] www.merck.com/product/patent/home.html, Retrieved on 3rd
November 2015.
[34] Drug Enforcement Administration, Department of Justice.
Schedules of controlled substances: placement of suvorexant
into Schedule IV. Final rule. Fed Regist. 2014; 79(167):51243-7.
[35] Boss C. Orexin receptor antagonists--a patent review (2010 to
August 2014). Expert Opin Ther Pat. 2014; 24(12):1367-1381.
[36] Https://en.wikipedia.org/wiki/Suvorexant#Interactions;
Retrieved on 3rd November 2015.
[37] Hoyer D. Neuropeptides. 2013; 47(6):447-488.
[38] Scammell TE, Winrow CJ. Orexin receptors: Pharmacology and
therapeutic opportunities. In: Cho AK, editor. Annual Review of
Pharmacology and Toxicology. Palo Alto California: Annual
Reviews; 2011. pp. 243–266.
[39] Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and
antagonists for treatment of sleep disorders. Rationale for development
and current status. CNS Drugs.2013;27(2):83-90.